Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Renal Cell 2Carcinoma, Medullary 2Zollinger-Ellison Syndrome 1Vipoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Paraganglioma 1Neuroendocrine Tumors 1Neoplastic Syndromes, Hereditary 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia 1Kidney Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Glioblastoma 1Congenital Abnormalities 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Brain Neoplasms 1Birt-Hogg-Dube Syndrome 1Advanced Malignant Solid Neoplasm 1

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic Digestive System Neuroendocrine Tumor G1 × Everolimus × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡